1

2
Motohiro Arasaki, Hideo Ishitsuka, Isami Kuruma, Masanori Miwa, Chikako Murasaki, Nobuo Shimma, Isao Umeda: N.sup.4 -(substituted-oxycarbonyl)-5-deoxy-5-fluorocytidine compounds, compositions and methods of using same. Hoffmann La Roche, George M Gould, George W Johnston, Robert A Silverman, December 5, 1995: US05472949 (24 worldwide citation)

The invention relates to N.sup.4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine derivatives which are useful as an agent for treating tumors, pharmaceutical compositions including the same, a method of treating tumors and a method of preparing N.sup.4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluo ...


3
Kazuteru Yokose, Nobuo Shimma, Miyako Kamata, Masahiro Aoki, Tatsuo Ohtsuka: Pyrido(3,2,1-IJ)-1,3,4 benzoxadiazine derivatives. Hoffmann La Roche, Jon S Saxe, Bernard S Leon, A Kate Huffman, January 31, 1989: US04801584 (20 worldwide citation)

The invention is concerned with tricyclic compounds of the formula ##STR1## wherein R.sup.1 is a hydrogen atom or a carboxy-protecting radical; R.sup.2 is a hydrogen atom or a lower alkyl radical which may be substituted with a halogen atom; R.sup.3 and R.sup.4 independently are a hydrogen atom or a ...


4
Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda: 4′-Substituted nucleoside derivatives as inhibitors of HCV RNA replication. Roche Palo Alto, Brian L Buckwalter, October 27, 2009: US07608601 (12 worldwide citation)

The present invention relates to the use of nucleoside derivatives of formula I wherein B signifies a 9-purinyl residue B1 of formula or a 1-pyrimidyl residue B2 of formula wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof; for the treatment of ...


5
Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda: 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication. Roche Palo Alto, Brian L Buckwalter, December 6, 2011: US08071567 (12 worldwide citation)

The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.


6
Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Nobuo Shimma, Takuo Tsukuda: 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication. Roche Palo Alto, Brian L Buckwalter, March 29, 2011: US07915232 (11 worldwide citation)

The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof which inhibit HCV polymerase and are useful for treating a patient suffering from a HCV infection and to pharmace ...


7

8
Kazuteru Yokose, Nobuo Shimma, Mikayo Kamata, Masahiro Aoki, Tatsuo Ohtsuka: Pyrido(3,2,1-IJ)-1,3,4-benzoxadiazine derivatives. Hoffmann La Roche, Jon S Saxe, Bernard S Leon, A Kate Huffman, September 5, 1989: US04864023 (8 worldwide citation)

The invention is concerned with tricyclic compounds of the formula ##STR1## wherein R.sup.1 is a hydrogen atom or a carboxy-protecting radical; R.sup.2 is a hydrogen atom or a lower alkyl radical which may be substituted with a halogen atom; R.sup.3 and R.sup.4 independently are a hydrogen atom or a ...


9

10
Kazuo Hattori, Tohru Ishikawa, Hideo Ishitsuka, Yasunori Kohchi, Nobuhiro Oikawa, Nobuo Shimma, Hitomi Suda: 5-deoxy-cytidine derivatives. Hoffmann La Roche, George W Johnston, Patricia S Rocha Tramaloni, Robert A Silverman, September 5, 2000: US06114520 (5 worldwide citation)

Novel 5'-deoxy-cytidine derivatives represented by the general formula (I) ##STR1## wherein R.sup.1 is a hydrogen atom or a group easily hydrolyzable under physiological conditions; R.sup.2 is a hydrogen atom, or --CO--OR.sup.4 group [wherein R.sup.4 is a saturated or unsaturated, straight or branch ...